Search results for: Multi-Indication Medicines
Filter search results
How to Manage Data Governance in an Era of Real World Evidence (RWE): Working Towards a Set of International Standards
24 November 2015
…and using it to support decision-making by regulators and payers is changing. Regulatory flexibilities and increasing public pressure to facilitate earlier access to medicines (e.g. through adaptive pathways or early…
Incentives for New Drugs and Vaccines to Tackle Anti-Microbial Resistance
16 May 2017
…poor countries. Additional ways of rewarding R&D are required. Mechanisms designed to encourage companies to undertake R&D on new medicines are generally characterised as either “push” or “pull” programs. “Pull”…
Making Outcome-based Payments a Reality in the NHS: A Research Collaboration between OHE, RAND Europe and King’s College London
15 May 2018
…outcome measures and patient experience; and Amanda Cole, who has led or contributed to projects relating to improving efficiency and resource allocation in cancer care, expediting access to new medicines…
Quality of Life in Long-term Cancer Survivors: Implications for Future Health Technology Assessments in Oncology
3 July 2018
…in recent decades due in part to pharmaceutical advances, with a growing range of increasingly effective and targeted medicines being developed, such asimmunotherapies. In the economic modelling of such treatments,…
Recommendations for Making Outcome-based Payments a Reality in the NHS: An Application to Cancer Drugs
21 February 2019
…to speed up access to new medicines, as suggested by the 2016 Accelerated Access Review, is for there to be more flexible pricing mechanisms. A payment model that is gaining…
Press Release: Proposed International Price Index Effectively Outsources Pharmaceutical Policy Decisions to Other Countries
29 October 2019
…markedly from the U.S. and give the government a central role in purchasing medicines, in contrast to the greater reliance on the private market seen in the U.S.” OHE has…
Opportunities to Increase Efficiency in Healthcare
6 October 2020
…rational use of medicines, and iv) Healthcare-Associated Infections (HCAIs). Case studies were developed, supplemented by workshops with stakeholders from Poland, Germany, Sweden, The Netherlands, and Spain. We identified examples of…
Virtual ISPOR European 2020
10 November 2020
…presents an in-depth analysis by the OHE on Adaptive Pathways for Tumour Agnostic Medicines in Various Developed Markets. While challenges for Tumour Agnostic medicines are similar in various countries, solutions will likely have…
Real Option Value and Path Dependence in Oncology Innovation
1 April 2014
Based on an OHE Lunchtime Seminar, this publication addresses a persistent issue: how to adequately reward innovation through the pricing of new medicines given the limitations of the information available…